Stock Spotlights Archives - Page 106 of 116

MondayDec 11, 2017 5:16 pm

CannabisNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Develops Cannabis-Based Therapeutics in Response to Opioid Epidemic

Emerging pharmaceutical and IP development company Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) is using scientific research and development to stake out its spot in the medical marijuana industry. An article discussing this reads: “Veritas Pharma’s mission is to develop and commercialize the most effective cannabis strains, backed by clinical data. This innovative research and development path aims to solve the critical need for real science to support claims surrounding medical marijuana. The company’s approach, combined with its strategic alliances, will effectively address the medical community’s concerns over the complexities of cannabis potency, efficacy, quality and content in the…

MondayDec 11, 2017 3:53 pm

CannabisNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Utilizes Proprietary Advanced Biosynthesis Process to Develop Cannabinoids-based Therapies

InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) remains focused on discovering potential breakthrough cannabinoid-based therapies by utilizing its proprietary cannabinoid biosynthesis process and its bioinformatics drug and disease targeting tool. An article discussing this reads: “Other biopharmaceutical companies may produce cannabinoids in the laboratory using chemical synthesis, but there’s a litany of drug development efforts with synthetic molecules that have failed. The proprietary biosynthesis process used by InMed Pharmaceuticals, Inc.’s (CSE: IN) (OTCQB: IMLFF) is unique. Producing cannabinoids that are identical to naturally occurring compounds is transformative for drug development. By using its proprietary process, InMed is able to manufacture exact…

MondayDec 11, 2017 3:39 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Sets its Sights on Booming Global Cannabis Industry

Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) patented delivery technology, DehydraTECH™ has positioned the company at the forefront of the thriving global cannabis industry. A recent article discussing this reads: “LXRP’s technology enables improved delivery of bioactive substances via oral ingestion that results in increased absorption without the need for unhealthy practices of inhalational dosing that result in damaging affects to the lungs. The technology also eliminates the need for co-administration with unhealthy sugars or sweeteners in delivery that are commonly used to mask the bitter tastes. With DehydraTECH™, bioactive substance delivery is improved by combining molecules with certain fatty acids…

FridayDec 08, 2017 12:42 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) DehydraTech™ Shines in Vegas Lights

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) attracted a lot of attention in Las Vegas at this year’s Marijuana Business Conference & Expo due to increased awareness about potential health benefits of cannabinoids and an increased demand for improved CBD-based edibles. A recent article highlights keen interest in Lexaria’s patented DehydraTECH™ delivery technology, stating, “Lexaria’s proprietary technology has been awarded patents in the U.S. and Australia, and it has patents pending in more than 40 other countries. Furthermore, it is the only company in the world to date that has a patent allowed for the oral delivery of all non-psychoactive cannabinoids,…

FridayDec 08, 2017 12:41 pm

CannabisNewsBreaks – Skinvisible, Inc. (SKVI) Poised for Growth More than Skin Deep

Skinvisible (OTCQB: SKVI) is poised for growth in the booming global topical drug delivery market. A recent article highlights the company’s positioning, stating, “The Nevada-based Company, which develops topical, transdermal and mucosal polymer-based drug delivery systems and formulations that incorporates its patent-pending technology for combining hydrophilic and hydrophobic polymer, is a player in an industry poised to double in size over the next seven years. A new market research report estimates the global topical drug delivery market will grow at a CAGR of 9.2% from USD 101.7 billion in 2016 to reach USD 205.1 billion by 2024. This is good…

FridayDec 08, 2017 12:14 pm

CannabisNewsBreaks – Grey Cloak Tech Inc. (GRCK) Targets Massive CBD Market Through Eqova Life Sciences Subsidiary

Grey Cloak Tech (OTCQB: GRCK) is positioning itself to profit from the growing cannabinoid (“CBD”) market through its wholly owned subsidiary Eqova Life Sciences. An article discussing this reads: “Eqova Life Sciences recently exhibited the company’s CBD products at the Integrative Medicine Summit in Denver, Colorado, which was attended by over 200 medical professionals. As part of the exhibition, Eqova Life Sciences also debuted its new CannaBio Salve, an innovative topical salve infused with several aromatic natural oils. The company’s formulations combine the scientifically-validated, powerful benefits of cannabinoids in standardized products which are then distributed to patients under the care…

WednesdayDec 06, 2017 3:28 pm

CannabisNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Featured in Visual Capitalist Company Spotlight

Pre-clinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) was recently highlighted in a company spotlight article by Visual Capitalist. The article features an infographic that breaks down the company’s development of novel cannabinoid-based therapies from start to finish. Among other areas of interest, Visual Capitalist provided an in-depth look into InMed's Bioinformatics assessment tool, Biosynthesis cannabinoid manufacturing process, and drug pipeline of new cannabinoid treatments. To view the full infographic, visit http://cnw.fm/5afgV About InMed InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery…

TuesdayDec 05, 2017 11:54 am

CannabisNewsBreaks – Marijuana Company of America, Inc. (MCOA) Further Strengthens Positioning in the Cannabis and Industrial Hemp CBD Markets

Marijuana Company of America (OTC: MCOA) has established a commanding presence in the cannabis and industrial hemp cannabidiol ("CBD") markets, as well as the related services supply chain, creating an umbrella over a diverse portfolio of cannabis- and hemp-based companies. In positioning for continued growth of the booming market, with projections that global sales of cannabis will climb to $31.4 billion (http://cnw.fm/Y0xp2), a recent article highlights a strategic joint venture, “In September 2017, MCOA entered into a joint venture with Global Hemp Group Inc. (OTC: GBHPF) (CSE: GHG), a Canadian public company, focused on conducting an industrial hemp pilot program…

MondayDec 04, 2017 1:10 pm

CannabisNewsBreaks – Cannabis Demand in Canada Creates Considerable Opportunity for ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF)

As Canada prepares for the legalization of recreational marijuana in July 2018, analysts are noting a shortage of supplies compared to expected demand for cannabis products. The demand is expected to exceed about 1.3 million pounds, easily outpacing current annual production of 20,000 pounds by the country’s licensed producers. That creates tremendous opportunities for Canada’s top cultivators with the ability to expand their operations and increase supply. An article discussing this reads: “ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF), has been licensed in good standing since 2014 with no history of product recalls, and proprietary computer-controlled production systems that have bolstered…

ThursdayNov 30, 2017 2:47 pm

CannabisNewsBreaks – India Globalization Capital, Inc.’s (NYSE: IGC) Future Business Strategy

India Globalization Capital (NYSE American: IGC) is strategizing the marketing of its products and select target markets for continued growth. A recent article highlights next year’s and future year’s prospects and IGC plans, stating, “[IGC] sees opportunities in 2018, primarily from the distribution, in Germany, of its cannabinoid-based therapies, including IGC-AD1 (Hyalolex). It also sees the commercialization in 2018 of Hyalolex in a non-inebriating liquid supplement version. IGC has identified a number of U.S. states, as well as Canada and Germany, as target markets in the future.” To view the full press release, visit http://cnw.fm/cqF9e About IGC IGC is engaged in…

News and publishing service for cannabis related companies

Contact us: 303.498.7722

Breaks Categories: Stock Spotlights